Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last €14.40 EUR
Change Today -0.261 / -1.78%
Volume 200.0
3O8 On Other Exchanges
As of 3:04 PM 07/29/15 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

201 Elliott Avenue West

Seattle, WA 98119

United States

Phone: 206-676-5000

Fax: 206-676-5005

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops and commercializes products targeting inflammation, coagulopathies, and disorders of the central nervous system. Clinical Programs PharmacoSurgery Platform The company generates from its PharmacoSurgery platform proprietary products that are combinations of therapeutic agents designed to act simultaneously at multiple discrete targets to block preemptively the molecular-signaling and biochemical cascade caused by surgical trauma and to provide clinical benefits both during and after surgery. These products are supplied in pre-dosed, pre-formulated, single-use containers and added to standard surgical irrigation solutions, delivered intraoperatively to the site of tissue trauma throughout the surgical procedure. The company's PharmacoSurgery platform is based on low-dose combinations of therapeutic agents delivered directly to the surgical site throughout the duration of the procedure to inhibit preemptively inflammation and other problems caused by surgical trauma and to provide clinical benefits both during and after surgery. The company's PharmacoSurgery products specifically comprise active pharmaceutical ingredients (APIs), contained in generic drugs already approved by the U.S. Food and Drug Administration (FDA), with established profiles of safety and pharmacologic activities. Omidria (OMS302)-Ophthalmology Omidria is being developed for use during intraocular lens replacement, including cataract and other lens replacement surgery. Omidria is a proprietary combination of ketorolac, an anti-inflammatory API, and phenylephrine, a mydriatic, or pupil dilating, API. FDA-approved drugs containing each of these APIs have been used in ophthalmological clinical practice, and both APIs are contained in generic, FDA-approved drugs. In November 2013, the FDA conditionally accepted Omidria as the proposed brand name for OMS302 in the U.S. and in 2013, the European Medicines Agency (EMA) accepted Omidria as the proposed brand name for OMS302 in the European Union (EU). The company completed two pivotal Phase 3 clinical trials that evaluated Omidria. In addition to Omidria, the company has six other clinical-stage development programs in its pipeline. The company also has a pipeline of preclinical programs, as well as two additional platforms: one capable of unlocking new G protein-coupled receptor drug targets and the other used to generate antibodies. For each of its products and programs, the company has retained all manufacturing, marketing and distribution rights. OMS103-Arthroscopy OMS103 is the company's PharmacoSurgery product being developed for use during arthroscopic procedures, including partial meniscectomy surgery, and is designed to provide a multimodal approach to block preemptively the inflammatory cascade induced by arthroscopy. OMS103 is a proprietary combination of anti-inflammatory/analgesic APIs, specifically amitriptyline, ketoprofen and oxymetazoline. In 2012, the company completed a multicenter, double-blind, Phase 3 clinical trial comparing OMS103 to vehicle control in 344 patients undergoing arthroscopic partial meniscectomy surgery. The company is redesigning its Phase 3 clinical program in arthroscopic partial meniscectomy surgery to include reduction of early postoperative pain as the primary endpoint. In addition, the company is evaluating alternative approaches to make OMS103 commercially available, such as through a registered outsourcing facility without the need to conduct any additional clinical trials. PDE10 Programs - OMS824 for Schizophrenia and Huntington's disease Phosphodiesterase 10, or PDE10, is an enzyme that is expressed in the areas of the brain strongly linked to diseases that affect cognition, including schizophrenia and Huntington's disease. The company's proprietary compound OMS824 inhibits PDE10 and is being developed in clinical programs for the treatment of cognitive disorders, including schizophrenia and Huntington's disease. The company is conducting an ongoing Phase 1 clinical program evaluating the safety, tolerability and pharmacokinetics of


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
3O8:GR €14.40 EUR -0.261

3O8 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 3O8.
View Industry Companies

Industry Analysis


Industry Average

Valuation 3O8 Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 721.7x
Price/Book 28.3x
Price/Cash Flow NM Not Meaningful
TEV/Sales 623.9x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact OMEROS CORP, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at